Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Yin, Lihong ^a   Rao, Pravin ^a   Elson, Paul ^a   Wang, Jianghua ^b   Ittmann, Michael ^b   Heston, Warren D W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; LUCIFERASE; MESSENGER RNA; METRIBOLONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SMALL INTERFERING RNA; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; FUSION GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REPORTER GENE; TMPRSS2 ERG GENE; DRUG ANTAGONISM; DRUG EFFECT; GENE FUSION; GENE SILENCING; GENETICS; MALE; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE;

BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUCIFERASES; MALE; METRIBOLONE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROSTATE-SPECIFIC ANTIGEN; RNA, SMALL INTERFERING;

EID: 79959579512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021319     Document Type: Article

References (31)

1. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD, (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811.
2. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, et al. (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58: 4055-4060.
3. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, et al. (2003) Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 63: 2645-2648.
4. Tasch J, Gong M, Sadelain M, Heston WD, (2001) A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit Rev Immunol 21: 249-261.
5. Ross JS, Sheehan CE, Fisher HAG, Kaufaman RP Jr, Kaur P, et al. (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9: 6357-462.
6. Perner S, Hofer MD, Kim R, Shah RB, Li H, et al. (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38: 696-701.
7. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, et al. (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-34.
8. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, et al. (1999) Five different anti-prostate specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59 (13): 3192-8.
9. O'Keefe DS, Bacich DJ, Heston WD, (2004) Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58: 200-10.
10. Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, et al. (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 40 (12): 1754-61.
11. Mitsiades CS, Lembessis P, Sourla A, Milathianakis C, Tsintavis A, et al. (2004) Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metastasis 21: 495-505.
12. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, et al. (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48 (2): 326-334.
13. Tomlins S, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
14. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, et al. (2006) TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Research 66 (7): 3396-3400.
15. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2): 177-188.
16. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research 66 (17): 8337-8341.
17. Demichelis F, Fall K, Perner S, Andren O, Scmidt F, et al. (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26: 4596-4599.
18. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M, (2008) Pleiotropic biological activities of alternatively spliced TMPRSS2-ERG fusion gene transcripts. Cancer Research 68 (20): 8516-8524.
19. Sun C, Dobi A, Nohamed A, Li H, Thangapazham RL, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353.
20. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics 41 (5): 619-623.
21. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics 41 (5): 524-526.
22. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, et al. (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71 (3): 281-288.
23. Ghosh A, Heston WD, (2003) Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate 57 (2): 140-151.
24. Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ, (2011) Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the prostate cells. Mol Cell Endocrinol 331: 57-65.
25. Bonaccorsi L, Nesi G, Nuti F, Paqlierani M, Krausz C, et al. (2009) Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J Endocrinol Invest 32 (7): 590-6.
26. Attard G, Swennenhuis JF, Olmos D, et al. (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (7): 2912-2918.
27. Heinlein CA, Chang C, (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
28. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69 (1): 16-22.
29. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, et al. (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69 (20): 8141-8149.
30. Cai C, Wang H, Xu Y, Chen S, Balk SP, et al. (2009) Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 69 (15): 6027-6032.
31. Yu J, Yu J, Mani R, Cao Q, Brenner CJ, et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.